GlassScriptPhysician profile
Natela Levi
NPI 1467468256
$2,495.70
in general payments reported to CMS, 2019-2025
10 companies · $652 in 2025
The $652 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $125 · 2022: $376 · 2023: $487 · 2024: $418 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,159.98 | 2019-2025 | Rexulti |
| Alkermes, INC. | $723.17 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $125.00 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $125.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $125.00 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $109.54 | 2025 | Cobenfy |
| Glaxosmithkline, LLC. | $62.79 | 2019 | |
| Sanofi Pasteur INC. | $31.59 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $17.05 | 2025 | Neffy |
| Biomarin Pharmaceutical INC. | $16.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natela Levi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.